Peptic Ulcer Disease and H. pylori Infection: Common Questions and Answers

Area of Science:

• Gastroenterology
• Internal Medicine
• Pharmacology

Background:

• Peptic ulcer disease (PUD) is prevalent, with Helicobacter pylori (H. pylori) infection and nonsteroidal anti-inflammatory drug (NSAID) use as primary causes.
• Combined H. pylori and NSAID use significantly elevates the risk of bleeding ulcers.

Purpose of the Study:

• To outline the current management strategies for peptic ulcer disease.
• To emphasize the importance of H. pylori eradication and appropriate NSAID selection or co-therapy.

Main Methods:

• Review of current guidelines for H. pylori testing and treatment.
• Recommendations for NSAID use and ulcer risk mitigation.
• Discussion of diagnostic modalities and first-line eradication therapies.

Main Results:

• H. pylori test-and-treat strategy is key for patients under 60 with dyspepsia.
• Noninvasive H. pylori testing (urea breath or stool antigen) is preferred.
• Bismuth quadruple or concomitant therapy is recommended for H. pylori eradication due to resistance.
• PPI co-administration or switching to selective NSAIDs (e.g., celecoxib) can reduce NSAID-induced ulcers.
• H. pylori eradication halves the risk of ulcers in NSAID users.

Conclusions:

• Effective management of PUD relies on timely H. pylori diagnosis and eradication.
• Risk stratification and appropriate pharmacotherapy are crucial for preventing NSAID-related ulcers.
• Long-term proton pump inhibitor (PPI) use carries potential risks that warrant consideration.